Advancing Clinical Care and Research with Confidence
care trends across the nation.
Advancing Clinical Care and Research with Confidence
Gain tailored insights into cardiovascular trends across the nation.
The Challenge 
Patient Enrollment Is Time Consuming and Costly
egnite provides a more targeted, efficient way to conduct trials and research:
Find the Right Patients
at the Right Time
Using artificial intelligence and advanced data processing to pre-screen for eligible patients
Streamline Enrollment
Improve efficiencies by up to 55% compared to traditional screening techniques
Discover Key Drivers
of Patient Attrition
Enhance patient and site selection
PARTNERS
The Data 
Welcome to One of the Largest Ecosystems of Real-World Cardiovascular Data
Longitudinal, echo and EHR data validated by clinicians daily
Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly
Proprietary NLP transforms unstructured echo data into usable information
Geographically diverse dataset from across the U.S.
Proprietary NLP transforms unstructured echo data into usable information
Geographically diverse dataset from across the U.S.
Longitudinal, echo and EHR data validated by clinicians daily
Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly
*Data from egnite’s de-identified database of 26 teaching and non-teaching US institutions with appropriate permissions.
Our Products
egnite Therapy Accelerator
for existing therapies
for existing therapies
for clinical trials
egnite Research
Collaborate to answer contemporary questions in cardiovascular disease:
Heart
Failure
Atrial
Fibrillation
Mitral
Regurgitation
Mitral
Stenosis
Tricuspid
Regurgitation
Aortic
Regurgitation
Aortic
Stenosis
Presented or Published In
Testimonials
Leading life sciences organizations partner with egnite to expand the boundaries of research and care.
JenaValve
Ancora Heart
Resources
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.